Navigation Links
PDL BioPharma Elects Barry Selick to Its Board of Directors
Date:8/3/2009

INCLINE VILLAGE, Nev., Aug. 3 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced the appointment of Harold E. ("Barry") Selick, Ph.D., to the Company's Board of Directors.

"Barry's experience as a seasoned biotechnology executive and his extensive knowledge of PDL's humanization technology will allow him to make valuable contributions to our strategy and operations as we seek to maximize the value of our antibody humanization patents and related assets and monetize these assets for our stockholders," said John McLaughlin, president and chief executive officer of PDL.

Dr. Selick has served as chief executive officer of Threshold Pharmaceuticals since June 2002. From January 1999 to April 2002, he was chief executive officer of biotechnology company Camitro Corporation. From 1992 to 1999, he worked at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as vice president of Research. Prior to joining Affymax, he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he was a co-inventor of the technology underlying the creation of fully humanized antibody therapeutics and applied this technology to PDL's first product, Zenapax (R), which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
2. PDL BioPharma Announces Second Quarter 2009 Financial Results
3. PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009
4. DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller
5. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
6. Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
7. Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its Tai Drug Series
8. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
9. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
10. PDL BioPharma Announces Record Date for October 1 Dividend Payment
11. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... ... Louisans are well-aware of the following facts at present:, Flu ... having no effect on keeping this particularly bad strain of the flu away , ... or sniffling , These facts are well-known among the team at Woodard! ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... San Francisco ... iTero Element, the latest in 3-D scanning device which is capable of taking digital ... latest advances in dentistry, such as CAD CAM restorations , in terms of ...
(Date:1/15/2017)... Cary, NC (PRWEB) , ... January 15, 2017 , ... Whole Health Supply, LLC is ... CP-140L . There are also new avenues for purchase. , The 2017 edition has ... can cause issues for the older boomers as well as diabetics. This handle is reinforced ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor ... Radnor, Pennsylvania. As construction wraps up on the 14,000+ square foot climbing gym, the ... sixth location, including three in New Jersey and two in New York. With this ...
(Date:1/14/2017)... ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition ... in Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... freeze frame transition from one clip to the next. , To use “Cut-Out ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... , Jan. 16, 2017  Cumberland Pharmaceuticals Inc. (NASDAQ: ... Kenneth J. Krogulski , CFA to its Board of ... of Berkshire Asset Management LLC . He is ... independent SEC registered investment advisory firm with over $1.5 ... 37 years, experience in security analysis and portfolio management. ...
(Date:1/14/2017)... Jan. 14, 2017  Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... According ...
(Date:1/13/2017)... January 13, 2017 According ... and Equipment Market by Method (Biochemical (Calcium Phosphate, ... Protein Production), End User - Global Forecast to ... global market from 2016 to 2021. This market ... 2021 from USD 715.4 Million in 2016, at ...
Breaking Medicine Technology: